Table 2.
irAEs of special interest in elderly people treated with PD1/PD-L1 inhibitors.
| Ref | Drug | Setting | Age | Histology | PD-L1 TPS (%) |
Best Response |
irAEs | irAE Outcome |
irAE Treatment | ICIs therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| Nakako S, 2022 [144] | Pembrolizumab + Chemotherapy | NR | 72 | NSCLC | NR | NR | Delayed G4 neutropenia at 92 and 118 days after pembrolizumab discontinuation | Resolved | SC | Discontinued |
| Dhenin A, 2019 [153] | Pembrolizumab | 1L | 79 | ADC | 100 | CR | Rash, pericarditis, colitis and myasthenia gravis | Resolved | SC | Resumed |
| Cham J, 2021 [154] | Durvalumab | Post-CRT | 72 | ADC | 80 | NE | Myocarditis, myasthenia gravis, and myositis | Death | SC | Discontinued |
| Strickley JD, 2019 [135] | Nivolumab | 2L | 87 | NSCLC | NR | SD | Lichen Planus Pemphigoides | Resolved | SC | Discontinued |
| Gracia-Cazaña T [136] | Nivolumab | NR | 78 | SCC | NR | PD | Stevens-Johnson syndrome | Resolved | SC | Discontinued |
| Kim YE, 2019 [137] | Nivolumab | NR | 74 | NSCLC | NR | NR | Psoriasiform dermatitis | Resolved | Etanercept + Methotrexate | Discontinued |
| Lopez AT, 2018 [138] | Nivolumab | 1L | 72 | SCC | 0 | NR | Bollous pemphigoid | Resolved | SC | Discontinued |
| Cosimati A, 2020 [139] | Pembrolizumab | 1L | 77 | ADC | 55 | SD | Bollous pemphigoid | Resolved | SC + doxycycline, nicotinamide, and clobetasol propionate | Discontinued |
| Muto Y, 2020 [140] | Pembrolizumab | NR | 84 | NSCLC | ≥50% | CR | Bollous pemphigoid | Resolved | SC | Discontinued |
| Yoshikawa Y, 2021 [141] | Nivolumab | 1L | 75 | NSCLC | NR | NR | Secondary sclerosing cholangitis | Death | SC + mycophenolate mofetil | Discontinued |
| Hamoir C, 2018 [142] | Nivolumab | 2L | 71 | NSCLC | NR | PD | Intrahepatic cholangitis | Resolved | SC + Ursodeoxycholic acid | Discontinued |
| Gelsomino F, 2017 [143] | Nivolumab | NR | 79 | NSCLC | NR | PD | Cholangitis | Resolved | SC + Ursodeoxycholic acid | Discontinued |
| Nakamura M, 2020 [145] | Durvalumab | Post-CRT | 79 | ADC | NR | NR | Immune-related hepatitis | Resolved | SC | Discontinued |
| Miyauchi M, 2020 [146] | Nivolumab | NR | 79 | NSCLC | NR | NR | Type 1 diabetes mellitus | Ongoing | Insulin | Discontinued |
| Seo JH, 2022 [147] | Nivolumab | 2L | 74 | ADC | 40 | SD | Type 1 diabetes mellitus | Ongoing | Insulin | Discontinued |
| Matsuura N, 2018 [148] | Nivolumab | 2L | 78 | NSCLC | NR | NR | Type 1 diabetes mellitus | Ongoing | Insulin | Resumed |
| Kajal S, 2021 [149] | Nivolumab | 3L | 84 | ADC | NR | NR | Hypophysitis | Improved | SC | Resumed |
| Galliazzo S, 2022 [150] | Nivolumab | NR | 74 | SCC | NR | NR | Primary adrenal insufficiency | Improved | Glucocorticoid + mineralocorticoid | NR |
| Kim J, 2019 [151] | Nivolumab | 2L | 76 | NSCLC | 75 | PR | Myasthenia Gravis and Myopathy | Improved | SC + ivIg | Discontinued |
| Hasegawa Y, 2017 [152] | Nivolumab | 3L | 76 | ADC | NR | PD | Myasthenia gravis | Improved | SC + ivIg | Discontinued |
| Tan JL, 2019 [155] | Nivolumab | 2L | 74 | ADC | NR | NR | Myocarditis and complete atrioventricular block | Improved | SC | Discontinued |
| Semper H, 2016 [156] | Nivolumab | 2L | 75 | ADC | 0 | PR | Myocarditis | Improved | SC | Discontinued |
| Katsume Y, 2018 [157] | Pembrolizumab | 2L | 73 | NSCLC | NR | NR | Myocarditis and complete atrioventricular block | Improved | SC | Discontinued |
| Samejima Y, 2020 [158] | Nivolumab | 2L | 79 | SCC | NR | PR | Severe Heart Failure | Improved | Diuretics, | Discontinued |
| Berry EC, 2022 [159] | Atezolizumab | 2L | 83 | ADC | NR | NR | Arteritic Anterior Ischemic Optic Neuropathy | NE | SC + Methotrexate | Discontinued |
| Gupta S, 2020 [160] | Durvalumab | Post-CRT | 80 | NSCLC | NR | NR | Vasculitis (blue toe syndrome) | Improved | SC | Discontinued |
| Suwa S, 2022 [161] | Atezolizumab | 2L | 76 | NSCLC | NR | NR | Vogt–Koyanagi–Harada Disease-like Uveitis | Improved | SC | Discontinued |
| Shiral AC, 2016 [162] | Nivolumab | 4L | 73 | SCC | NR | NR | Acute Interstitial Nephritis | Improved | SC | Resumed |
| Nivolumab | 4L | 78 | ADC | NR | NR | Acute Interstitial Nephritis | Resolved | SC | Discontinued | |
| Taki T, 2020 [134] | Pembrolizumab | 2L | 75 | ADC | 25–49 | PR | Tubulointerstitial Nephritis | Improved | SC | Discontinued |
| Takahashi N, 2018 [163] | Nivolumab | 2L | 74 | ADC | NR | PR | Goodpasture’s disease | Death | SC + plasma exchange | Discontinued |
| Narumi Y, 2018 [164] | Nivolumab | 2L | 75 | SCC | NR | PD | Neuromyelitis optica spectrum disorder | Improved | SC + plasma exchange | Discontinued |
| Makri OE, 2022 [165] | Pembrolizumab | 2L | 76 | NSCLC | NR | NR | Optic Neuritis | Improved | SC | Discontinued |
| Richard K, 2017 [166] | Nivolumab | 2L | 74 | NSCLC | NR | NR | Encephalitis | Improved | SC | Discontinued |
| Lou Y, 2019 [167] | Nivolumab | 2L | 73 | ADC | NR | PR | Recurrent Hypereosinophilia | Improved | NR | Discontinued |
| Turgeman I, 2017 [168] | Nivolumab | 3L | 74 | ADC | NR | PR | Severe Neutropenia | Improved | SC | Discontinued |
| Tabchi S, 2016 [169] | Nivolumab | 2L | 74 | ADC | NR | NR | Severe agranulocytosis | NR | SC + ivIg | Discontinued |
| Naqash AR, 2019 [170] | Pembrolizumab | 2L | 74 | ADC | 50 | PR | Recurrent febrile neutropenia | Death | SC | Discontinued |
| Karakas Y, 2017 [171] | Nivolumab | 2L | 78 | NSCLC | NR | PD | Immune Thrombocytopenia | Improved | SC | Discontinued |
| Okawa S, 2019 [172] | Pembrolizumab | 1L | 78 | SCC | >50 | PR | Autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis | Improved | SC | Discontinued |
Abbreviations. 1L: first line; 2L: second line; 3L: third line; 4L: fourth line; ADC: adenocarcinoma; SCC: squamous cell carcinoma; NE: not evaluable; NR: not reported; CR: complete response; SD: stable disease; PD: progressive disease; CRT: chemoradiotherapy; SC: systemic corticosteroid; ivIg: intravenous immunoglobulin.